Carbon Biosciences announces new appointments to its Board of Directors and Scientific Advisory Board

– Carol Ann SatlerMD, PhD, FACC, FAHA, FAAP joins the Board, adding key clinical experience to lead the continued, non-clinical development of heart and lung diseases –

– Lloyd KlicksteinMD joins the Scientific Advisory Board to provide additional research and translational strategy expertise, complementing the Company’s gene therapy expertise –

– Recent additions highlight Carbon Bioscience’s evolution beyond a cutting-edge vector platform company to a pipeline-focused organization with significant translation efforts and a clinical proof-of-concept milestones focus –

WALTHAM, Holy Mass, May 22, 2024 /PRNewswire/ — Carbon Biosciences, a pre-clinical biotechnology company developing genetic medicines to treat lung and heart diseases, announced the appointment of Carol Ann Satler MD, PhD, FACC, FAHA, FAAP to the Carbon Biosciences Board of Directors and Lloyd Klickstein, Ph.D., Doctor of Medical Sciences to the Scientific Council. Dr. Satler joins as Carbon’s second independent board member. Dr. Klickstein joins Carbon’s esteemed scientific advisory panel of experts in gene therapy drug development.

“We are pleased to welcome both Dr. Satler and Dr. Klickstein to the Carbon team at this pivotal moment in the company’s evolution. Their appointments strengthen our leadership and expertise as we advance our cardiology and pulmonary programs into the clinic,” said Drs. Joel Schneider, president and CEO of Carbon Biosciences. “Dr. Satler is a world-class clinician with a demonstrated ability to combine groundbreaking scientific and clinical strategies to advance successful therapies. Dr. Klickstein is a renowned expert in translational biology with significant leadership and advisory experience from early research through global Phase 3 development across multiple biopharmaceutical organizations.”

“Carbon’s proprietary expertise in novel viral vectorization demonstrates great potential to overcome limitations currently hindering gene therapy programs,” said Dr. Satler. “I want to support the team in achieving its ambitious goals.” Dr. Satler is a physician executive with a track record of success in clinical development and medical affairs at fast-growing, innovative companies. Her work included strategic clinical development planning, launch and commercialization of products for the treatment of chronic diseases such as idiopathic pulmonary fibrosis and heart failure. Dr. Satler currently serves as Chief Medical Director of the Idiopathic Pulmonary Fibrosis Clinical Development Program at Puretech Health and as an independent board member of ViCardia Therapeutics. Previously, she was president, chief medical officer and board member of Respira Therapeutics.

The story continues

Dr. Satler is a graduate of doctoral studies at ul Case Western Reserve University, Cleveland, Ohio. She trained and practiced in pediatric medicine and cardiology at Boston Children’s Hospital and served on the faculty of Harvard Medical School. She has been elected a fellow of the American College of Cardiology, the American Heart Association, and the American Academy of Pediatrics.

“Carbon’s technology shows exciting potential, and I look forward to helping translate the company’s impressive vector science and non-clinical research efforts into successful development programs,” said Dr. Klickstein upon joining Carbon’s Scientific Advisory Board. Dr. Klickstein is a seasoned life sciences leader with nearly 20 years of experience, most recently as founder and CEO and then president and chief scientific officer of Versanis Bio (acquired by Eli Lilly and Company in 2023). Dr. Klickstein previously served as head of translational medicine at Novartis Institutes for Biomedical Research (NIBR) for 13 years. Prior to joining Novartis, he directed an NIH-funded basic science laboratory at Brigham & Women’s Hospital (BWH) in Boston, MA where he also conducted an active clinical practice. Dr. Klickstein completed his doctoral studies and received his Doctor of Medicine degree Harvard Universityhe completed postgraduate clinical training at BWH, is Board certified and recertified in internal medicine and rheumatology and immunology, and is a Fellow of the American College of Rheumatology.

Dr. Satler’s and Dr. Klickstein’s combined experience positions them to advise Carbon on its early-stage translational and clinical activities. They are well positioned to ensure that the company’s rigorous science packages underpin effective clinical development plans that include a biomarker strategy for early signal detection. The appointments of Dr. Satler and Dr. Klickstein further recognize the potential of Carbon’s technology and the near-term changes the company is rapidly moving toward.

About carbon biology:

Carbon Biosciences is a team of passionate people dedicated to developing drugs that expand the reach of genetic medicines in the treatment of devastating diseases. We combine the genetic diversity and power of viruses that have evolved over millions of years with the latest clinical and manufacturing advances in gene therapy. Our proprietary PAVE platform has the potential advantages of exceptional tissue specificity, higher payload, and durable treatment strategies across multiple modalities. Our goal: realize the power of natural virus evolution and fulfill the promise of genetic medicines.

Carbon Biosciences, Inc.
Investor and media contact

Beckett Hart
[email protected]

View original content to download multimedia: https://www.prnewswire.com/news-releases/carbon-biosciences-announces-new-appointments-to-board-of-directors-and-scientific-advisory-board-302152125. html

SOURCE Carbon Science